John Clarke to Chair Futura

RNS Number : 2026R
Futura Medical PLC
01 November 2011
 



For immediate release

1 November 2011

 

 

 

Futura Medical plc

("Futura" or "the Company")

 

Appointment of Non-Executive Chairman

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is delighted to announce the appointment of John Clarke, the highly experienced GlaxoSmithKline ("GSK") executive, as Non-Executive Chairman.

Mr Clarke has extensive experience of the healthcare sector, having worked at GSK for more than 35 years. In 2006 he was appointed President of GSK Consumer Healthcare, a position from which he recently stepped down. Under Mr Clarke's leadership, GSK Consumer Healthcare became one of the fastest-growing companies in its industry. It achieved 60% sales growth between 2006 and 2010, when it recorded a turnover of £5 billion.

Mr Clarke's appointment at Futura will be effective on 1 February 2012.

Mr Clarke will replace Dr William Potter, who will step down from the Board on 1 February 2012 but continue to play a key role as Futura's Chief Scientific Officer.  David Davies, Futura's Product Development Director, becomes Chief Development Director, reflecting the Company's increasing emphasis on its product pipeline.

John Clarke, Futura's Chairman Designate, commented: "I am delighted to be taking on the Chairmanship of Futura.  I am particularly impressed by the level of innovation at Futura, by the commercial potential of its late stage products and by the breadth of its product pipeline.  I look forward to assisting the Company in achieving its true potential."

James Barder, Futura's Chief Executive, said: "John Clarke is recognised as an outstanding leader in the consumer healthcare industry and we are therefore delighted that he has decided to join Futura at this exciting stage in our development. I would like to give my profound thanks to Bill Potter for his tenure as Chairman, and am delighted that he will be remaining with the Company as Chief Scientific Officer."

 

 

Additional information:

 

John Milne Clarke, age 62 years, holds no shares in Futura. He was President of GlaxoSmithKline Worldwide Consumer Healthcare.  He is a member of GlaxoSmithKline plc Corporate Executive Team and a director of the US-based Consumer Healthcare Products Association.

 

There are no further disclosures to be made in relation to Mr Clarke under Schedule 2(g) and (i) of the AIM rules.

 

 

 

For any further information please contact:

 

Futura Medical plc


James Barder, Chief Executive

Tel: +44 (0) 1483 685 670



mail to: james.barder@futuramedical.com

www.futuramedical.com



Nomura Code Securities Limited


Phil Walker / Giles Balleny

Tel:+44 (0)20 7776 1200



For media enquiries please contact:




Buchanan


Mark Court / Jessica Fontaine

Tel: +44 (0) 20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDFLFXFBFFFBK
UK 100

Latest directors dealings